ERBB2 and breast cancer: In this retrospective analysis including 98 breast cancer patients treated with anti-Her-2 therapy, we studied potential relationship between TILs infiltration, count of FOXP3+ Tregs, CD68+ Mφ and IL-17+ Th17 in both intratumoral and stromal site with patients’ survival.